Inhibition of Tamoxifen-stimulated Growth of an MCF-7 Tumor Variant in Athymic Mice by Novel Steroidal Antiestrogens1

Cancer Research

Volumn 49, Issue 15, 1989, Pages 4090-4093

  Gottardis, Marco M ^a   Jiang, Shun Yuan ^a   Jeng, Meei Huey ^a   Jordan, V Craig ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; ESTRADIOL; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN;

ANIMAL EXPERIMENT; BREAST CANCER; CELL CULTURE; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; MOUSE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMAL; BREAST NEOPLASMS; CELL DIVISION; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0024319781     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tormey, D. C., and Jordan, V. C. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res. Treat, 4:297-302,1984.
2. Baum, M., and other members of the Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as an adjuvant agent in the management of early breast cancer. Lancet, 1:257-261,1983.
3. Fisher, B., and other NASBP investigators. Prolonging tamoxifen for primary breast cancer: fmdings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial. Ann. Intern. Med., 106:649-654,1987.
4. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRQ. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet, 2:171-175,1987.
5. Jordan, V. C., Allen, K. E., and Dix, C. J. Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep., 64:745-759,1980.
6. Gottardis, M. M., and Jordan, V. C. The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47:4020-4027,1987.
7. Osborne, C. K., Boldt, D. H., Clark, G. M., and Trent J. M. Effects of tamoxifen in human breast cancer cell cycle kinetics: accumulation of cells in early G phase. Cancer Res., 43:3583-3585,1983.
8. Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. R., and Taylor, I. W. Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the Go/G phase of the cell. Eur. J. Cancer Gin. Oncol., 19: 615-621, 1983.
9. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25:127-205, 1984.
10. Tormey, D. C., Simon, R. M., Lippman, M. E., Bull, J. M., and Meyer, C. E. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat. Rep., 60:1451-1459,1976.
11. McIntosh, I. H., and Thynne, G. S. Tumor stimulation by antiestrogens. Br. J. Surg., 64:900-901,1977.
12. Plotkin, D., Lechner, J. J., Jung, W. E., and Risen, P. J. Tamoxifen flare in advanced breast cancer. JAMA, 240: 2644-2646,1978.
13. Legault-Poisson, S., Jolivet, J., Poisson, R., Peretta-Pkcoli, M., and Band, P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep., 63:1839-1841, 1979.
14. Smith, I. E., Harris, A. L., Morgan, M., Ford, H. T., Gazet, J.-C., Harmes, C. L., White, H., Parsons, C. A., Villardo, A., Walsh, G., and McKinna, J. A. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br. Med. J., 283:1432-1434,1981.
15. Murray, R. M. L., and Pitt, P. Aminoglutethimide in tamoxifen-resistant patients: the Melbourne experience. Cancer Res., 42 (suppl. 1): 3437s-3441s, 1982.
16. Buzdar, A. O., Powell, K. C., and Blumenschein, G. R. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res., 42 (suppl. 1): 3448s-3450s, 1982.
17. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23: 1189-1196, 1987.
18. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48:5183-5187, 1988.
19. Satyaswaroop, P. G., Zaino, R. J., and Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res., 44:4006-4010,1984.
20. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48:812-814, 1988.
21. Anzai, Y., Holinka, C. F., Kuramota, H., and Gurpide, E. Stimulatory effects of hydroxytamoxifen on proliferation of human endometrial carcinoma cells of the Ishikawa (1-1) line. Endocrine Soc. Prog. Abstr., 174:613,1988.
22. Robinson, S. P., and Jordan, V. C. Antiestrogenic action of toremifene on hormone-dependent, independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res., 49:1758-1762,1989.
23. Jordan, V. C., Robinson, S. P., and Welshons, W. V. Resistance to antiestrogen therapy. In: D. Kessel, Resistance to Antineoplastic Drugs, pp. 403-427. Boca Raton, FL: CRC Press, 1988.
24. Jordan, V. C., and Robinson, S. P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc., 46:1870-1874, 1987.
25. Fomander, T., Rutquist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfverswérd, C., Skoog, L., Somell, A., Theve, T., Wilking, N., Asbergren, J., and Hjalmar, M. L. Adjuvant tamoxifen in early breast cancer occurrence of new primary cancers. Lancet, 1: 117-120, 1989.
26. Reddel, R. R., and Sutherland, R. L. Tamoxifen stimulation of human breast cancer proliferations in vitro. A possible model for tamoxifen tumor flare. Eur. J. Gin. Oncol., 20:1419-1424,1984.
27. Darbre, P. D., Curtis, S., and King, R. J. B. Effect of estradiol and tamoxifen on human breast cancer cells in serum-free culture. Cancer Res., 44: 2790-2793, 1984.
28. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. Proc. Nail. Acad. Sci. USA, 83: 2496-2500, 1986.
29. Cormier, E. M., and Jordan, V. C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur. J. Cancer Clin. Oncol., 25: 57-63, 1989.
30. Wakeling, A. E., and Bowler, J. Steroidal pure antiestrogens. J. Endocrinol., 112: R7-R10, 1987.
31. Jordan, V. C., and Koch, R. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology, 124: 1717-1726.